EI
NVCR icon

Ethic Inc’s NovoCure NVCR Stock Holding History

Ethic Inc’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,542
Closed -$213K – 1007
2023
Q1 		$213K Buy
+3,542
New +$283K 0.01% 884
2022
Q2 		– Sell
-2,630
Closed -$218K – 772
2022
Q1 		$218K Sell
2,630
-243
-8% -$17.9K 0.02% 688
2021
Q4 		$216K Buy
2,873
+241
+9% +$24.2K 0.02% 601
2021
Q3 		$306K Sell
2,632
-1,173
-31% -$177K 0.03% 470
2021
Q2 		$844K Buy
3,805
+2,215
+139% +$431K 0.1% 243
2021
Q1 		$210K Buy
+1,590
New +$252K 0.04% 457

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Ethic Inc's NVCR Position: Q2 2023 in Review

Ethic Inc sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 3,542 shares — an estimated $213K sold.

Ethic Inc first reported a position in NVCR in Q1 2021 and held it in 6 quarters. The position peaked at $844K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Ethic Inc reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Ethic Inc sold 3,542 NovoCure shares in Q2 2023, an estimated $213K.
  • Ethic Inc first reported a position in NovoCure in Q1 2021 and held it in 6 quarters.
  • Ethic Inc's NovoCure position peaked at $844K in Q2 2021.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Ethic Inc's 13F filing for Q2 2023, filed 14 Aug 2023.